In response to increasing prescription drug costs, the
University is raising the copays for prescription drug benefits
to $7 for generic drugs and $14 for brand name drugs in
most health plans, effective January 1, 2001.
The Benefits Office offers a series of five articles
to provide background on the reasons behind the co-pay increases
and information to help faculty and staff make the most
of their prescription drug benefits.
The University will increase prescription drug copay amounts
for many of its employee health plans effective January
1, 2001.
The current $5 copay for generic (non brand name) drugs
will increase to $7, and the $10 copay for brand name drugs
will increase to $14. The increase applies to all HMOs,
Point-of-Service plans, and the Blue Cross Blue Shield Comprehensive
Major Medical (CMM) plan. The change will not affect negotiated
union benefits or the United of Omaha portion of the BCBS/United
plan.
The escalating cost of prescription drugs---nationally
as well as across University plans---is the reason for the
increases. Year 2000 prescription drug costs for U-M employees
are projected to total about $29 million, which is approximately
22 percent of the University's total health care costs.
In recent years, U-M's prescription drug spending has increased
annually by about the same rate as the nation's: between
15 and 20 percent.
Some of the factors contributing to increased prescription
drug expenditures will be discussed in later articles. Generally,
they include increasingly aggressive diagnosis and prevention,
availability of new drugs to treat previously untreatable
conditions, pharmaceutical company marketing, and an aging
population using more medication.
The Benefits Office projects the copay increases will save
at least $1.7 million per year. That figure is based on
annual prescription totals for all affected health plan
members.
The Executive Officers based the decision to increase copays
on an extensive review of various cost-sharing options.
The Benefits Office began the process by alerting the Executive
Officers to the dramatic rise in prescription drug expenditures.
The Officers then asked the Benefits Office to provide data
on drug costs and utilization throughout U-M health plans
and to develop models for copay increases.
The models included estimated savings under four proposed
copay options, along with their advantages and disadvantages
to the University and health plan members. The Benefits
Office arrived at these proposals with the help of representatives
from William Mercer, Inc., a national consulting firm specializing
in group health care benefits.
U-M health care vendors provided rates for the various
copay models to show the impact each would have on the University's
health plan rates. The Benefits Office furnished the Executive
Officers with this data and also shared information on each
proposal with the Benefits Policy Advisory Committee. Comprised
of faculty and staff representatives from both academic
and nonacademic units, that committee regularly offers input
on benefits issues.
A random sample campus survey of faculty and staff perceptions
and attitudes on prescription drugs was conducted in June
of 1999. The survey data supported a consistent preference
of respondents to continue with flat copayment cost sharing
for prescription drugs over co-insurance cost sharing.
The Executive Officers selected the $7/$14 copay option
for offering the greatest savings to the University at the
fairest cost to health plan participants. The Benefits Office
estimated that this option will cost health plan members
an average of $10 to $70 per year.
This model encourages generic drug use, is easy to understand,
and enables participants to know exactly how much they will
pay out-of-pocket at pharmacies. The Executive Officers
concluded that this model is the best fit for all faculty
and staff groups within the institution.
A look at the University's history of prescription drug
coverage shows moderate increases in cost sharing over the
past decade. Click here to view the
history of prescription drug coverage at UM.